Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial

Aims In the EMPA‐REG OUTCOME trial, empagliflozin reduced risk of death from heart failure (HF) or hospitalization for heart failure (HHF) versus placebo in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease. We evaluated post hoc the degree to which covariates...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	ESC Heart Failure 2021-12, Vol.8 (6), p.4517-4527
Hauptverfasser:	Fitchett, David, Inzucchi, Silvio E., Zinman, Bernard, Wanner, Christoph, Schumacher, Martin, Schmoor, Claudia, Ohneberg, Kristin, Ofstad, Anne Pernille, Salsali, Afshin, George, Jyothis T., Hantel, Stefan, Bluhmki, Erich, Lachin, John M., Zannad, Faiez
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood pressure Body mass index Cardiac & Cardiovascular Systems Cardiology and cardiovascular system Cardiovascular System & Cardiology Diabetes Empagliflozin Heart failure Heart rate Hemoglobin High density lipoprotein Hospitalization Human health and pathology Life Sciences Life Sciences & Biomedicine Mediation analysis Original Science & Technology SGLT2 inhibitor Uric acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!